Heparin Induced Thrombocytopenia - 4T Score and Management

Key Points

• Use the 4Ts score before ordering HIT laboratory testing.
• A low 4Ts score usually rules out HIT and prevents harmful unnecessary treatment.
• Stop all heparin and begin non-heparin anticoagulation for intermediate/high-probability acute HIT.
• HIT is a thrombotic disorder even when the presenting finding is thrombocytopenia.
• Do not start warfarin until platelet recovery.
• Avoid routine platelet transfusion unless bleeding or high procedural risk justifies it.
• PF4 immunoassay positivity is not equivalent to platelet-activating HIT; functional testing improves specificity.
• Review hidden heparin exposures such as flushes and coated devices.

Algorithm

1. Calculate the 4Ts score from platelet fall, timing, thrombosis and alternative causes.
2. If low probability, continue evaluating other thrombocytopenia causes and generally avoid HIT testing.
3. If intermediate/high probability, stop all heparin immediately.
4. Send PF4/heparin immunoassay and functional assay according to local testing pathway.
5. Start an appropriate non-heparin anticoagulant based on organ function, stability and bleeding risk.
6. Screen for clinically silent thrombosis as recommended, including bilateral leg ultrasound in acute isolated HIT.
7. Delay warfarin until platelet recovery; reverse early warfarin with vitamin K if already started.
8. Determine anticoagulation duration based on whether thrombosis occurred and document HIT clearly for future care.

Clinical Synopsis & Reasoning

HIT is not simply thrombocytopenia while receiving heparin. The characteristic pattern is a platelet count fall of more than about 50 percent from the postoperative or treatment peak, usually beginning 5 to 10 days after heparin exposure. The absolute platelet count may remain above 150 x 10^9/L early. Rapid-onset HIT can occur within hours when a patient has circulating antibodies from recent heparin exposure. Thrombosis can precede the platelet fall and may involve DVT/PE, limb arteries, stroke, myocardial infarction, adrenal veins, skin necrosis, or catheter thrombosis.

Calculate the 4Ts score using thrombocytopenia magnitude, timing, thrombosis/skin reaction, and other causes of thrombocytopenia. A low score has a high negative predictive value and generally avoids unnecessary HIT testing and alternative anticoagulation. Intermediate/high probability warrants PF4/heparin immunoassay, with a functional assay such as serotonin release assay used to confirm clinically important antibodies when available. Immunoassays are sensitive but can be positive in patients without platelet-activating HIT, especially after cardiac surgery. Review all heparin sources, including flushes, heparin-coated catheters and LMWH.

Treatment Strategy & Disposition

When 4Ts probability is intermediate or high, discontinue all heparin and start a non-heparin anticoagulant unless bleeding risk precludes it. Options include argatroban, bivalirudin, fondaparinux, danaparoid where available, or a DOAC in selected clinically stable patients. Choice depends on renal and hepatic function, need for urgent procedures, critical illness, bleeding risk, and drug availability. Patients with acute HIT should generally receive therapeutic-intensity anticoagulation because thrombosis risk is high, even when thrombosis has not yet been documented, with individualized intensity for high bleeding risk.

Do not initiate warfarin before platelet recovery, commonly at least 150 x 10^9/L, because early protein C depletion can cause venous limb gangrene and skin necrosis. If warfarin was already given, stop it and give vitamin K. Avoid routine platelet transfusion unless there is active bleeding or a high-risk procedure because transfused platelets may provide additional substrate for thrombosis. Screen for silent lower-extremity DVT in acute isolated HIT and consider ultrasound of a catheterized upper extremity according to ASH guidance. Treat HIT-associated thrombosis for about 3 to 6 months; isolated HIT is anticoagulated at least until platelet recovery and generally not beyond 3 months without another indication.

Epidemiology / Risk Factors

• HIT occurs more often with unfractionated heparin than LMWH and more often in surgical than medical populations.
• The syndrome is uncommon but carries high thrombosis risk if untreated.
• Thrombosis may be venous or arterial and can occur before thrombocytopenia is recognized.
• Mortality and limb loss historically were substantial before routine recognition and non-heparin anticoagulation.

Investigations

Alternative Anticoagulants

Pharmacology

Prognosis / Complications

• Platelets usually recover after heparin cessation and effective alternative anticoagulation.
• Untreated HIT has a high short-term risk of thrombosis.
• HIT with thrombosis requires a standard therapeutic anticoagulation course after the acute immune phase.
• Future heparin decisions depend on whether HIT is acute, subacute or remote and should be documented carefully.

Patient Education / Counseling

• Explain that HIT is an immune clotting reaction to heparin, not a simple bleeding disorder caused by low platelets.
• Tell every future clinician about confirmed HIT and keep it in the allergy/adverse-reaction list.
• Review bleeding precautions for the non-heparin anticoagulant.
• Seek urgent care for new leg/arm swelling, chest pain, dyspnea, focal neurologic symptoms, abdominal pain or limb ischemia.
• Do not self-discontinue alternative anticoagulation when the platelet count normalizes; duration depends on thrombosis status.

Notes

The biggest diagnostic error is testing everyone with thrombocytopenia and then treating a weakly positive PF4 assay as HIT. A low 4Ts score should usually stop the HIT pathway. At the other extreme, waiting for the laboratory result in a high-probability patient leaves the patient exposed to a dangerous prothrombotic immune process.

ASH guidance also emphasizes silent thrombosis screening and avoiding routine platelet transfusion. The diagnosis should remain prominently documented after discharge because inadvertent heparin re-exposure during a later hospitalization or procedure can create preventable risk.

References

1. ASH Clinical Practice Guidelines: Heparin-Induced Thrombocytopenia — Link